The Major Depressive Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Major Depressive Disorder Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Major Depressive Disorder Market.
Some of the key takeaways from the Major Depressive Disorder Pipeline Report:
- Companies across the globe are diligently working toward developing novel Major Depressive Disorder treatment therapies with a considerable amount of success over the years.
- Major Depressive Disorder companies working in the treatment market are SIMR Biotech, Gerbera Therapeutics, Alto Neuroscience, Cerevel Therapeutics, Alto Neuroscience, Beckley Psytech, Alto Neuroscience, Janssen Research & Development, Ehave Inc., Neumora Therapeutics, Inc., Janssen Research & Development, LLC, Neurocrine Biosciences, Otsuka Pharmaceutical, Ancora Bio, Sirtsei Pharmaceuticals, Intra-Cellular Therapies, Inc., Axsome Therapeutics, Fidia Farmaceutici s.p.a., Janssen-Cilag Ltd., Suven Life Sciences Limited, Gilgamesh Pharmaceuticals, Bausch Health Americas, Boehringer Ingelheim, and others, are developing therapies for the Major Depressive Disorder treatment
- Emerging Major Depressive Disorder therapies in the different phases of clinical trials are- Major depressive disorder therapeutic, NORA-520, ALTO 203, CVL 354, ALTO-300, BPL-003, ALTO 100, Seltorexant, Ketamine Hydrochloride, NMRA-335140, Aticaprant, NBI-1070770, SEP-363856, ANC-501, SP-624, Lumateperone, Solriamfetol, Liposom Forte, Esketamine, Ropanicant, GM-1020, bupropion hydrobromide, BI 1569912, and others are expected to have a significant impact on the Major Depressive Disorder market in the coming years.
- In April 2024, The initial participant has been randomly assigned in a phase II clinical study (NBI-1070770-MDD2029) evaluating the effectiveness, safety, and tolerance of the experimental drug NBI-1070770 in adults diagnosed with major depressive disorder (MDD).
- In April 2024, Alto Neuroscience has declared the commencement of its Phase II clinical trial, which is double-blind and involves both single and multiple doses. The study aims to evaluate the pharmacodynamic effects of ALTO-203 in patients diagnosed with major depressive disorder (MDD), alongside assessing its safety, tolerability, and pharmacokinetics.
- In November 2023, Cybin has unveiled encouraging findings from the Phase 2 trial, demonstrating favorable safety and efficacy outcomes for CYB003, its exclusive deuterated psilocybin analog. This compound is under development as a treatment for major depressive disorder (MDD).
Major Depressive Disorder Overview
Major Depressive Disorder (MDD), commonly referred to as clinical depression or simply depression, is a mental health condition characterized by persistent feelings of sadness, hopelessness, and a lack of interest or pleasure in activities. It is a serious medical illness that can negatively impact how you feel, think, and handle daily activities.
Get a Free Sample PDF Report to know more about Major Depressive Disorder Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/major-depressive-disorder-pipeline-insight
Emerging Major Depressive Disorder Drugs Under Different Phases of Clinical Development Include:
- Major depressive disorder therapeutic: SIMR Biotech
- NORA-520: Gerbera Therapeutics
- ALTO 203: Alto Neuroscience
- CVL 354: Cerevel Therapeutics
- ALTO-300: Alto Neuroscience
- BPL-003: Beckley Psytech
- ALTO 100: Alto Neuroscience
- Seltorexant: Janssen Research & Development
- Ketamine Hydrochloride: Ehave Inc.
- NMRA-335140: Neumora Therapeutics, Inc.
- Aticaprant: Janssen Research & Development, LLC
- NBI-1070770: Neurocrine Biosciences
- SEP-363856: Otsuka Pharmaceutical
- ANC-501: Ancora Bio
- SP-624: Sirtsei Pharmaceuticals
- Lumateperone: Intra-Cellular Therapies, Inc.
- Solriamfetol: Axsome Therapeutics
- Liposom Forte: Fidia Farmaceutici s.p.a.
- Esketamine: Janssen-Cilag Ltd.
- Ropanicant: Suven Life Sciences Limited
- GM-1020: Gilgamesh Pharmaceuticals
- bupropion hydrobromide: Bausch Health Americas
- BI 1569912: Boehringer Ingelheim
Major Depressive Disorder Route of Administration
Major Depressive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Major Depressive Disorder Molecule Type
Major Depressive Disorder Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Major Depressive Disorder Pipeline Therapeutics Assessment
- Major Depressive Disorder Assessment by Product Type
- Major Depressive Disorder By Stage and Product Type
- Major Depressive Disorder Assessment by Route of Administration
- Major Depressive Disorder By Stage and Route of Administration
- Major Depressive Disorder Assessment by Molecule Type
- Major Depressive Disorder by Stage and Molecule Type
DelveInsight’s Major Depressive Disorder Report covers around 75+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Major Depressive Disorder product details are provided in the report. Download the Major Depressive Disorder pipeline report to learn more about the emerging Major Depressive Disorder therapies
Some of the key companies in the Major Depressive Disorder Therapeutics Market include:
Key companies developing therapies for Major Depressive Disorder are – Johnson & Johnson, Pfizer, Inc., AstraZeneca plc, Merck & Co., GlaxoSmithKline plc, Eli Lilly and Company, Sanofi S.A., Shire plc, Novartis AG, Janssen Pharmaceutical, Inc., and others.
Major Depressive Disorder Pipeline Analysis:
The Major Depressive Disorder pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Major Depressive Disorder with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Major Depressive Disorder Treatment.
- Major Depressive Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Major Depressive Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Major Depressive Disorder market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Major Depressive Disorder drugs and therapies
Major Depressive Disorder Pipeline Market Drivers
- The prevalence of this rare soft tissue sarcoma increases, it creates a demand for improved diagnostic tools, treatment options, and supportive care services are some of the important factors that are fueling the Major Depressive Disorder Market.
Major Depressive Disorder Pipeline Market Barriers
- However, with a limited patient population, pharmaceutical companies face challenges in recouping the substantial expenses incurred during the research, development, and clinical trial phases of new treatments and other factors are creating obstacles in the Major Depressive Disorder Market growth.
Scope of Major Depressive Disorder Pipeline Drug Insight
- Coverage: Global
- Key Major Depressive Disorder Companies: SIMR Biotech, Gerbera Therapeutics, Alto Neuroscience, Cerevel Therapeutics, Alto Neuroscience, Beckley Psytech, Alto Neuroscience, Janssen Research & Development, Ehave Inc., Neumora Therapeutics, Inc., Janssen Research & Development, LLC, Neurocrine Biosciences, Otsuka Pharmaceutical, Ancora Bio, Sirtsei Pharmaceuticals, Intra-Cellular Therapies, Inc., Axsome Therapeutics, Fidia Farmaceutici s.p.a., Janssen-Cilag Ltd., Suven Life Sciences Limited, Gilgamesh Pharmaceuticals, Bausch Health Americas, Boehringer Ingelheim, and others
- Key Major Depressive Disorder Therapies: Major depressive disorder therapeutic, NORA-520, ALTO 203, CVL 354, ALTO-300, BPL-003, ALTO 100, Seltorexant, Ketamine Hydrochloride, NMRA-335140, Aticaprant, NBI-1070770, SEP-363856, ANC-501, SP-624, Lumateperone, Solriamfetol, Liposom Forte, Esketamine, Ropanicant, GM-1020, bupropion hydrobromide, BI 1569912, and others
- Major Depressive Disorder Therapeutic Assessment: Major Depressive Disorder current marketed and Major Depressive Disorder emerging therapies
- Major Depressive Disorder Market Dynamics: Major Depressive Disorder market drivers and Major Depressive Disorder market barriers
Request for Sample PDF Report for Major Depressive Disorder Pipeline Assessment and clinical trials
Table of Contents
1. Major Depressive Disorder Report Introduction
2. Major Depressive Disorder Executive Summary
3. Major Depressive Disorder Overview
4. Major Depressive Disorder- Analytical Perspective In-depth Commercial Assessment
5. Major Depressive Disorder Pipeline Therapeutics
6. Major Depressive Disorder Late Stage Products (Phase II/III)
7. Major Depressive Disorder Mid Stage Products (Phase II)
8. Major Depressive Disorder Early Stage Products (Phase I)
9. Major Depressive Disorder Preclinical Stage Products
10. Major Depressive Disorder Therapeutics Assessment
11. Major Depressive Disorder Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Major Depressive Disorder Key Companies
14. Major Depressive Disorder Key Products
15. Major Depressive Disorder Unmet Needs
16 . Major Depressive Disorder Market Drivers and Barriers
17. Major Depressive Disorder Future Perspectives and Conclusion
18. Major Depressive Disorder Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/